Compare ARK Genomic Revolution ETF (ARKG) vs Royal Bank of Canada (RY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Royal Bank of Canada — how do they compare? ARK Genomic Revolution ETF trades at $41, while Royal Bank of Canada trades at $210.93 (market cap $292.49B). The key difference: Royal Bank of Canada pays a 2.42% dividend while ARK Genomic Revolution ETF pays none, and Royal Bank of Canada is trading nearer its 52-week high, ARK Genomic Revolution ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | RY | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $43.57 | $211.09 |
52-Week Low | $23.09 | $128.46 |
Market Cap | — | $292.49B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Royal Bank of Canada (RY) trades at $211.09, up 1.21% today, with a bullish technical signal and strong fundamental performance. Recent quarterly earnings consistently beat estimates, with Q1 2026 EPS of $2.84 exceeding the $2.81 forecast. Revenue grew to $66.53B in 2025, and net income margin improved to 31.85%. The company maintains a solid dividend, recently increasing it to $1.76 per share, and announced a share repurchase program.
RY's outlook is positive, supported by earnings momentum and shareholder returns, but faces risks from economic softness and high valuation multiples. Analyst sentiment is mixed, with a majority hold rating, reflecting caution amid rich valuations. The stock's current price near resistance at $211 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
